Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BVS857 in Severe Burn Subjects
NCT02074995Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2014
- Primary completion
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of BVS857 in burn injury, sponsored by Novartis. Started Feb 2014; status: terminated.
02
Drugs
BVS857
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT02074995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074995.